Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency

DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Primary tabs

Hermans, Cédric [UCL] Eeckhoudt, Stéphane [UCL] Lambert, Catherine [UCL]

Document type	Article de périodique (Journal article) – Lettre à l'éditeur
Publication date	2012
Language	Anglais
Journal information	"Thrombosis and Haemostasis : international journal for vascular biology and medicine" - Vol. 107, no. 6, p. 1189-1191 (2012)
Peer reviewed	yes
Publisher	Schattauer GmbH ((Germany) Stuttgart)
issn	0340-6245
Publication status	Publié
Affiliations	UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire UCL - (SLuc) Service d'hématologie UCL - (SLuc) Service de biologie hématologique
MESH Subject	Anticoagulants ; Severity of Illness Index ; Skin ; Warfarin ; Young Adult ; Benzimidazoles ; Drug Eruptions ; Drug Substitution ; Female ; Humans ; Necrosis ; Protein C Deficiency ; Pyridines
Links	http://hdl.handle.net/2078/124951[Handle] http://www.ncbi.nlm.nih.gov/pubmed/22398431[Pubmed] https://doi.org/10.1160/TH11-11-0788[DOI]

Bibliographic reference	Hermans, Cédric ; Eeckhoudt, Stéphane ; Lambert, Catherine. Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. In: Thrombosis and Haemostasis : international journal for vascular biology and medicine, Vol. 107, no. 6, p. 1189-1191 (2012)
Permanent URL	http://hdl.handle.net/2078/124951